Results 111 to 120 of about 21,820 (216)

Will Ceftazidime-Avibactam Replace Polymyxins in Asia?

Clinical Infectious Diseases, 2021
Sock Hoon, Tan, Narendran, Koomanan, Shimin Jasmine, Chung, Andrea Lay-Hoon, Kwa   +3 more
openaire   +2 more sources

**In vitro** antibacterial activity of the ceftazidime-avibactam (NXL104) combination against **Pseudomonas aeruginosa** clinical isolates

, 2012
: The beta-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa ...
Goossens, Herman, Coleman, Kenneth, Girard, Anne-Marie, Claudon, Monique, Black, Michael T., Levasseur, Premavathy, Miossec, Christine   +6 more
core  

In-vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase

, 2015
Ceftazidime-avibactam is active against most Enterobacteriaceae isolates with KPC carbapenemases. We investigated whether this activity could be compromised by mutation.
Warner, Marina, Mustafa, Nazim, Livermore, David, Nichols, Wright W., Jamrozy, Dorota, Woodford, Neil, Mushtaq, Shazad   +6 more
core   +1 more source

Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance

mSystems
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive.
Jie Wei, Jinyu Huang, Chunhong Zou, Shimei Shen, Barry N. Kreiswirth, Ailong Huang, Shifeng Huang, Liang Chen, Deqiang Wang, Siqiang Niu   +9 more
doaj   +1 more source

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +1 more source

In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review

New Microbes and New Infections
Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients.
Abolfazl Rafati Zomorodi, Leila Ghanbari_Afra, Hossein Faridafshar, Seyed Nooreddin Faraji, Fatemeh Zarepour, Maryamosadat Mavaei, Mohammad Rahmanian   +6 more
doaj   +1 more source

Ceftazidime-avibactam susceptibility against Escherichia coli and Klebsiella pneumoniae

Iranian Journal of Microbiology
Background and Objectives: Carbapenem-resistant Enterobacteriaceae (CRE) infections are extremely difficult to treat and have a high fatality rate. The study's primary goal was to determine the rate of ceftazidime-avibactam susceptibility using disc diffusion and E-Test, as well as to evaluate the agreement between the two methods.
Arun Sachu, Alice David
openaire   +3 more sources

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Ceftazidime/avibactam for specified infections [PDF]

Australian Prescriber, 2020
openaire   +3 more sources

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae

Antimicrobial Agents and Chemotherapy
Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4
Thomas Lavoie, Teresa Sierra, Katie Daffinee, Jason M. Pogue, Brahim Achour, Kerry LaPlante   +5 more
doaj   +1 more source